1980
DOI: 10.1007/bf00254018
|View full text |Cite
|
Sign up to set email alerts
|

Actinomycin D in the treatment of advanced breast cancer

Abstract: Actinomycin D is generally administered by serial low-dose injection over 5-10 days. Recent recognition of prolonged serum and tissue half-lives suggests that high-dose intermittent injecton should be equally effective and less toxic. An intermitten single dose schedule was selected for this phase II trial of actinomycin D in 23 patients with advanced breast cancer refractory to standard combination chemotherapy. The drug was given in doses of 0.75-1.5 mg/m2 at 2-week intervals or on days 1 and 8 of 28-day tre… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
9
0

Year Published

1999
1999
2023
2023

Publication Types

Select...
4
1
1

Relationship

0
6

Authors

Journals

citations
Cited by 10 publications
(10 citation statements)
references
References 4 publications
1
9
0
Order By: Relevance
“…That is consistent with an idea that BDNF takes part in sprouting events in epilepsy (17,18). Moreover, in the presented study we used Actinomycin D which has been already in use in treatments of several types of cancer (83)(84)(85). However, in terms of the potential use of Actinomycin D for the treatment of brain diseases including epilepsy, its administration would be challenging due to difficulties of its distribution through the brain-blood barrier (58).…”
Section: Preincubation Of Hippocampal Cultures Withsupporting
confidence: 84%
“…That is consistent with an idea that BDNF takes part in sprouting events in epilepsy (17,18). Moreover, in the presented study we used Actinomycin D which has been already in use in treatments of several types of cancer (83)(84)(85). However, in terms of the potential use of Actinomycin D for the treatment of brain diseases including epilepsy, its administration would be challenging due to difficulties of its distribution through the brain-blood barrier (58).…”
Section: Preincubation Of Hippocampal Cultures Withsupporting
confidence: 84%
“…The c-Jun N-terminal kinase (JNK) pathway, which is involved in phosphorylation of c-Jun, is also activated by ActD, which leads to apoptosis (Kleeff, Kornmann, Sawhney, & Korc, 2000). ActD has been used as an experimental drug to treat Wilm's tumor, soft tissue sarcomas, testicular cancer, and lymphomas (Grimm et al, 1980). Parthenolide (PTL), a sesquiterpene lactone, is obtained from few plants (Tanacetum parthenium).…”
mentioning
confidence: 99%
“…We document the survival of a child with only minor long-term sequelae following a massive overdose of dactinomycin that was much larger than any previously reported. The most commonly reported toxicities of dactinomycin include mucositis, bone marrow suppression, hepatic dysfunction, and erythematous rashes [1][2][3][4]. These side effects are usually dose-dependent and transient.…”
Section: Discussionmentioning
confidence: 99%
“…
Dactinomycin is an antineoplastic antibiotic used in the treatment of a variety of tumors, including Wilms tumor, soft-tissue sarcomas, testicular cancer, lymphomas, and breast cancer [1][2][3]. The reported extrahematopoetic toxicities are mild and include nausea, vomiting, ulcers of the gastrointestinal mucosa, and elevation of liver enzymes.
…”
mentioning
confidence: 99%